Correspondence on 'Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis' by Rizos et al

In their review and meta-analysis, Rizos et al1 reported that omega-3 supplementation at low and higher dosages showed no or weak associations with cardiovascular disease (CVD) outcomes, respectively. More recent reviews also showed protective activity of omega-3 against CVD outcomes. For instance, omega-3 (2–4 g/day) in patients with high or very high triglyceride (TG) levels decreases significantly high-sensitivity C reactive protein (hsCRP), lipoprotein-associated phospholipase A2 (Lp-PLA2), and oxidised low density lipoprotein (LDL)-cholesterol (oxLDL) levels, and the reduction of hsCRP is enhanced when co-administered with a statin;2 hs-CRP, Lp-PLA2 and oxLDL levels are associated with the risk of the major CVD events; and long-term omega-3 administration (over a median of 4.9 years) significantly decreases acute myocardial infraction (AMI), coronary revascularisation, unstable angina, cardiovascular death or stroke. Omega-3 fatty acids exhibit a beneficial effect on CVD via reprogramming of TG-rich lipoproteins metabolism, decreasing inflammatory mediators (cytokines and leukotrienes),...
Source: Heart - Category: Cardiology Authors: Tags: Correspondence Source Type: research